

Madison Park Group is pleased to announce that its client, Real Life Sciences (RLS), a leading clinical data privacy and regulatory compliance provider, has been acquired by Susquehanna Growth Equity-backed MediSpend. The addition of RLS bolsters MediSpend’s ability to support life sciences companies and contract research organizations (CROs) in navigating complex regulatory requirements to disclose clinical trial results data while protecting participant privacy and intellectual property.
RLS’ solutions address compliance requirements across major regulatory bodies, including EMA (EU) 536/2014, EMA Clinical Data Publication Policy 0070, Health Canada Public Release of Clinical Information (PRCI), FDA disclosure mandates and more. RLS was backed by Lock 8 Partners.
About Real Life Sciences
Based in Wayne, PA, RLS is a specialized provider of clinical transparency solutions provider enabling end-to-end data privacy, global disclosure management and compliance for life sciences. Their flagship platform, RLS Protect, enables life sciences companies and CROs to comply with regulatory requirements while protecting participant privacy and commercially confidential information.
For more information, please visit the Real Life Sciences website.
About MediSpend
MediSpend is a global technology provider helping life sciences companies grow their businesses compliantly. The company’s SaaS Compliance suite is built to manage HCP/O engagement, spend and transparency reporting, grants management and contract management. MediSpend is a portfolio company of Susquehanna Growth Equity. MediSpend provides commercial compliance solutions for the largest pharmaceutical, medical device and dental companies as well as emerging biotech companies across the world.
For more information, please visit the MediSpend website.